Press Release
Sector Spotlight: Orphan Drug Developers With Significant Upside
–News Direct–
The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record of strong recoveries, with the sector typically seeing double-digit gains after a downturn. This is something investors shouldnt ignore.
This recent turnaround can be credited to a robust increase in fundraising efforts and an uptick in IPOs, reaching levels not seen since the peak of the mid-pandemic market boom.
According to the Financial Times, drug developers raised $6 billion in equity capital markets in January, the largest total since February 2021 a period when biotech stocks hit their all-time high. Moreover, the SPDR S&P Biotech ETF (XBI) returned 28.7% over the past six months alone, clearly illustrating investors' rising confidence in the biotech rebound.
Identifying biotech stocks with the potential to deliver superior returns is no easy feat. There are specific milestones that companies can achieve to signal positive momentum to investors. For example, smaller biotech companies may have received the nod from regulatory authorities such as the FDA, or new breakthroughs from clinical trials, to offer a compelling investment opportunity.
With that in mind, two stocks that investors should consider looking at are Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) and Kiniksa Pharmaceuticals (NASDAQ:KNSA).
Cardiol Therapeutics lead product is CardiolRx, a small molecule therapy that appears on track to bring major disruption to the pericarditis market.
CardiolRx received a vote of confidence as it was granted Orphan Drug Designation (ODD) by the FDA for the treatment of pericarditis back in February, illustrating the potential of the drug. Apart from providing a seven-year term of market exclusivity upon final FDA approval, the ODD also positions Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees, and certain tax credits.
The U.S. Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders, defined as one that affects fewer than 200,000 people in the U.S. There are approximately 160,000 cases of recurrent pericarditis in the U.S. annually, which includes 38,000 cases with a recurrence. Having secured FDA approval, Cardiol Therapeutics is an exemplary company likely to attract biotech investors seeking assurance in smaller firms.
While the stock had a significant rally on the backdrop of this news and continues to show strength, we believe that there is still potential for further upside.
Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) is expected to release topline data in June for its Phase 2 MAvERIC-Pilot clinical trial, which if positive, could unlock significant shareholder value. Several analysts have already indicated that they are highly optimistic that the data could be a catalyst, with one analyst noting that CardiolRxs potential to be a safe, new approach to RP (recurrent pericarditis) treatment is underappreciated.
CardiolRx stands out when compared to the only FDA-approved therapy because it is administered orally and expected to be offered as a first-line therapy for pericarditis, opening it up to an even bigger opportunity as it could be prescribed at the first occurrence.
Orphan drugs have become lucrative business opportunities because these drugs command premium drug pricing, with the average price for an orphan drug at $32,000 per year per patient according to a 2021 study published in the journal Rare Diseases & Journal of Orphan Drugs.
That could explain why analysts who have been tracking CRDL are so bullish on the stock. For instance, Joe Gantoss of Chimera Research Group says he wont be surprised to see Cardiols price break past the 3-year high at $4.96, while analyst Vernon Bernardino of H.C. Wainwright & Co. reiterated their Buy rating and issued a $9.00 price target.
That would imply that Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) has a potential upside of about 300% from its current share price.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) offers some insight into the revenue potential of an orphan drug that treats recurrent pericarditis.
So far, KNSA has had a great run, gaining about 36% over the past year and trading at about $18.00 per share despite challenges in the sector. It is currently valued at $1.3 billion. Kiniksas portfolio of assets includes ARCALYST, the first and only FDA-approved therapy for recurrent pericarditis.
For some context, the FDA granted Breakthrough Therapy designation to ARCALYST for recurrent pericarditis in 2019; the FDA granted Orphan Drug exclusivity to ARCALYST in March 2021 for the treatment of recurrent pericarditis and a reduction in the risk of recurrence in adults and pediatric patients 12 years of age and older. The European Commission granted Orphan Drug Designation to ARCALYST for the treatment of idiopathic pericarditis in 2021.
Sales of ARCALYST were $38.5 million in 2021; $122.5 million in 2022; $233.2 million in 2023 further reaffirming the massive revenue potential for treating recurrent pericarditis. For the first quarter of 2024, ARCALYST sales were $78.9 million representing 85% year-over-year growth.
Furthermore, since its launch in April 2021, approximately 2,000 prescribers have written ARCALYST prescriptions for recurrent pericarditis, illustrating the massive demand for effective recurrent pericarditis therapies.
Going forward, Kiniksa anticipates that it will bring in between $370 million and $390 million in 2024, up from the earlier guidance of $360 million to $380 million. The revised outlook represents roughly 63% year-over-year growth at the midpoint.
Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Cardiol Therapeutics to assist in the production and distribution of content related to CRDL. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.
Contact Details
RazorPitch Inc
Mark McKelvie
+1 585-301-7700
Company Website
View source version on newsdirect.com: https://newsdirect.com/news/sector-spotlight-orphan-drug-developers-with-significant-upside-473277125
RazorPitch CRDL, KNSA
COMTEX_453280304/2655/2024-06-03T07:03:00
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Steven Dossou Recognized Globally as a Leading Venture Strategist and International Keynote Speaker Driving Innovation Across Emerging Ecosystems
Steven Dossou is an international keynote speaker, investor, and Venture Strategist specializing in early-stage capital, innovation ecosystems, and founder development. His work spans Europe, Africa, and North America, supporting investors, founders, corporate teams, and policy-driven institutions. Dossou has been featured on CBS, NBC, FOX, and other major global platforms for his contributions to entrepreneurship and venture strategy.
Lisbon, Portugal, 10th Dec 2025 — Steven Dossou, an international keynote speaker, investor, and globally recognized Venture Strategist, is rapidly gaining influence across Europe, Africa, and emerging innovation markets. Known for his expertise in venture ecosystems, early-stage capital, and innovation-led growth, Dossou is increasingly invited to speak at conferences, corporate strategy events, and economic development forums focused on the future of entrepreneurship and investment.
Operating at the intersection of venture strategy, founder development, and ecosystem transformation, Dossou brings a rare combination of hands-on investment experience, cross-border insight, and human-centered leadership methodology to the global stage.
A Venture Strategist Shaping Conversations Around Innovation, Investing, and Economic Growth
Dossou’s work focuses on three strategic pillars that define modern innovation-driven economies:
1. Venture Strategy & Early-Stage Capital
Dossou advises investors, innovation hubs, and startup communities on how to structure angel portfolios, evaluate cross-border opportunities, and navigate emerging markets. His frameworks help new and experienced investors develop a disciplined, long-term approach to early-stage capital deployment.
2. Founder Performance & Investment Readiness
He specializes in teaching founders how to think, communicate, and operate like venture-building leaders. This includes investor storytelling, resilience under uncertainty, and strategic decision-making — core skills required to attract capital and scale sustainably.
3. Innovation & Ecosystem Development
Dossou collaborates with universities, accelerators, corporate innovation units, and government-backed programs to support ecosystem-building initiatives, cross-border collaboration, and the development of entrepreneurial infrastructure.
His global experience — spanning Europe, Africa, the Middle East, and North America — gives him a uniquely multicultural understanding of how talent, capital, and innovation intersect to shape economic competitiveness.
A Compelling Personal Story Paired with Strategic Insight
Born in Togo and now working internationally, Dossou’s journey from humble beginnings to global influence informs much of his work as a strategist and educator.
His speaking style blends:
- real-world venture experience
- empirical insights on founder behavior
- structured investment thinking
- global market understanding
- and practical transformation framework
“The future belongs to ecosystems that understand how venture strategy, human capability, and innovation work together,”
Dossou says.
“My work is about helping founders, investors, and institutions navigate complexity with clarity and intention.”
His story has been featured on CBS, NBC, FOX and in numerous entrepreneurship and innovation forums.
Trusted by Investors, Corporates, Universities, Accelerators, and Innovation Agencies
Dossou is frequently engaged by organizations seeking strategic clarity on:
- early-stage investing and venture building
- scaling founder capability
- innovation-led organizational transformation
- cross-border investment opportunities
- Africa–Europe collaboration in emerging innovation markets
- global entrepreneurship education
He works with:
- Startup accelerators & incubators
- Angel investor groups & LP communities
- Corporate innovation teams
- Universities and business schools
- Governments and economic development entities
His sessions offer a combination of thought leadership, practical frameworks, and actionable insights tailored to diverse audiences.
Extending His Strategic Work Through IRIS Vision Capital
Through IRIS Vision Capital, Dossou develops programs that strengthen both sides of the venture equation: founders seeking capital and investors seeking access to quality deal flow. The platform operates across Portugal, Finland, Spain, and select African markets, focusing on:
- investment readiness
- investor education
- deal-flow development
- ecosystem partnerships
- cross-border collaboration
While IRIS amplifies his impact operationally, Dossou’s speaking and advisory work continues to stand independently as a sought-after global offering.
A Leading Voice for Global Innovation and the Future of Venture Ecosystems
Dossou is regularly invited to contribute insights on topics such as:
- The evolution of venture capital in emerging markets
- Global innovation trends and new economic models
- The psychology and performance patterns of founders
- Early-stage investment strategy and risk frameworks
- The role of cross-border ecosystems in shaping the future of work and entrepreneurship
- How organizations and governments can accelerate innovation capacity
This positions him as a key figure for conferences and institutions seeking thought-provoking, strategic, and globally informed perspectives.
About Steven Dossou
Steven Dossou is an international keynote speaker, investor, and Venture Strategist specializing in early-stage capital, innovation ecosystems, and founder development. His work spans Europe, Africa, and North America, supporting investors, founders, corporate teams, and policy-driven institutions. Dossou has been featured on CBS, NBC, FOX, and other major global platforms for his contributions to entrepreneurship and venture strategy.
Media Contact
Website: www.stevendossou.com
Speaking Engagements: Book Steven Dossou for your next keynote or innovation event
Collaboration Inquiries: info@stevendossou.com
Media Contact
Organization: Steven Dossou
Contact Person: Erin Thabos
Website: https://www.stevendossou.com/
Email: Send Email
Contact Number: +351920140152
Address:Lisbon
City: Lisbon
State: Lisbon
Country:Portugal
Release id:38864
The post Steven Dossou Recognized Globally as a Leading Venture Strategist and International Keynote Speaker Driving Innovation Across Emerging Ecosystems appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Dominica, 10th Dec 2025 – In 2025, retail trading continues to evolve as mobile technology and crypto-linked derivatives reshape investor behavior worldwide. Usage of mobile trading applications is growing fast, driven by improved smartphone performance, optimized trading apps, and a rising wave of younger investors favoring on-the-go access. At the same time, crypto CFDs have surged in popularity, offering structured exposure to volatile digital assets without the complexity of wallets or blockchain transactions.
This shift towards mobile and crypto-derivatives has pushed multi-asset platforms into the spotlight. Traders increasingly demand consistent, unified access to forex, indices, commodities, equities, and digital assets under a single interface. One company responding to this demand is ScoreCM. The firm expanded its crypto CFD offering in 2025 while enhancing its mobile infrastructure, aiming to provide seamless access across asset classes.
As crypto-linked derivatives gain regulatory clarity and institutional liquidity deepens, integrated mobile-first platforms are expected to define the next generation of retail trading. Crypto CFD adoption and multi-asset capabilities are rapidly becoming essential features for brokers seeking to meet modern investor expectations.
About ScoreCM
ScoreCM operates as a multi-asset trading provider offering structured access to traditional and digital markets through forex, commodities, indices, equities, and crypto CFD products. The company prioritizes platform stability, transparent pricing, and the development of modern trading solutions to meet the evolving needs of global traders.
Media Contact
Organization: ScoreCM Ltd
Contact Person: Fırat Oçak
Website: https://www.scorecm.com
Email: Send Email
Contact Number: +442038075948
Address:c/o 40 Kennedy Avenue, Roseau, Commonwealth of Dominica
Country:Dominica
Release id:38863
Disclaimer: This press release is for informational purposes only and does not constitute financial advice, investment recommendation, or offer to buy/sell any financial products. Trading and investing involve risk, and past performance is not indicative of future results.
The post Mobile Trading and Crypto CFDs Highlight 2025 FinTech Trends appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Bulgarian tour operator Belprego Travel has announced its own charter programs to Doha, Qatar, for the New Year 2026, Valentine’s Day, and spring, featuring direct flights from Sofia and accommodation in five-star hotels.
Sofia, Bulgaria, 10th Dec 2025 – Belprego Travel, a licensed Bulgarian tour operator established in 2010, has announced its own charter programs to Qatar for the 2026 tourism season. The new offerings include direct charter flights from Sofia to Doha for the New Year holidays, a romantic Valentine’s Day package, and multiple spring departures with Qatar Airways.
New Year 2026 program
The flagship New Year program runs from December 27, 2025, to January 3, 2026, featuring an 8-day itinerary with 7 nights. Travelers can choose from a variety of hotels in Doha.
Package prices start from €818 per person for standard accommodation, with premium options reaching up to €3,433 per person at select luxury hotels. All packages include round-trip charter flights with BH Air with 20 kg checked and 7 kg carry-on luggage, airport transfers, and medical insurance with €10,000 coverage.
The premium All-Inclusive option at Rixos Gulf Doha 5-star includes a New Year’s gala dinner, priced from €2,392 per person.
An alternative New Year program with Qatar Airways runs from December 27, 2025, to January 2, 2026, offering 7 days and 6 nights at JW Marriott Marquis City Center Doha, priced from €1,713 per person.
Valentine’s Day and spring programs
The Valentine’s Day program runs from February 9–16, 2026, featuring 8 days and 7 nights at a five-star hotel in Doha. Prices start from €920 per person, including direct Qatar Airways flights, transfers, and bed & breakfast accommodation.
Spring 2026 dates are scheduled for February 27, March 13, March 20, and March 28, all operating with direct Qatar Airways flights. The eight-day program includes five-star hotel accommodation with breakfast, with prices from €997 per person.
Optional excursions
Belprego offers a variety of optional excursions for all Qatar programs. Available options include a 4-hour Doha city tour visiting the Museum of Islamic Art, Katara Cultural Village, The Pearl Island, and Souq Waqif market for €75. Desert safari and beach from €100. Evening cruises on a traditional dhow boat start from €50, and a full-day excursion to Zekreet in Western Qatar, including a visit to Richard Serra’s East-West/West-East sculpture installation, is offered for €100.
Visa information
Bulgarian citizens with valid passports can enter Qatar without a pre-issued visa. A free visa is issued upon arrival at Hamad International Airport in Doha. Passports must be valid for at least six months after the date of departure from Qatar.
Company statement
“Qatar represents an exciting new destination for Bulgarian tourists seeking a unique combination of modern luxury and traditional Arab culture. Direct charter flights from Sofia make Doha more accessible than ever, and the diverse selection of hotels ensures options for every budget,” said Radoslava Beleganska, Managing Director of Belprego Travel.
About Qatar
Qatar is a peninsular nation on the Persian Gulf, known for its futuristic skyline, world-class museums, traditional markets, and unique desert landscapes where sand dunes meet the sea at the Inland Sea nature reserve. The capital Doha hosted the 2022 FIFA World Cup and has established itself as a leading tourist destination in the Middle East.
About Belprego Travel
Belprego Travel is a licensed Bulgarian tour operator established in 2010, with a nationwide presence through offices in Sofia, Plovdiv, Pazardzhik, Asenovgrad, Peshtera, and Mezdra. The company specializes in organizing charter programs and package holidays to exotic destinations worldwide, including Turkey, the Middle East, and beyond. With a dedicated team committed to long-term partnerships and personalized service, Belprego has built a strong reputation for delivering quality travel experiences at competitive prices.
Media Contact
Organization: Belprego Travel
Contact Person: Marketing
Website: https://www.belprego.com
Email: Send Email
Contact Number: +359883570057
City: Sofia
Country:Bulgaria
Release id:38808
The post Belprego Travel launches exclusive charter programs to Qatar for 2026 appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Steven Dossou Recognized Globally as a Leading Venture Strategist and International Keynote Speaker Driving Innovation Across Emerging Ecosystems
Mobile Trading and Crypto CFDs Highlight 2025 FinTech Trends
Belprego Travel launches exclusive charter programs to Qatar for 2026
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release1 week ago
Global Manufacturing Innovation Forum 2025 and Saudi–Dongguan Businesses Announced 17 Billion SAR Collaboration
-
Press Release1 week ago
Lumixus Canada Securities Ltd Officially Launched: Becomes Group’s North American Investment Management and Research Headquarters with $10 Million CAD Registered Capital
-
Press Release4 days ago
Author of Journey to Forever Meets with Film Producer to Discuss Screen Potential
-
Press Release4 days ago
The Attic Insulation Specialists Inc. Expands Full-Service Home Energy and Safety Solutions Across Southern California
-
Press Release5 days ago
Bougainville Launches Offshore Gaming and Financial Authorities
-
Press Release5 days ago
Operational Police Protective Services Introduces Elite Security Solutions for High-Profile Corporate and Entertainment Events
-
Press Release4 days ago
Jack Botanicals Sets New Industry Standard with Premium Quality Kratom and Best Kratom Vendor
-
Press Release5 days ago
Mary Drucker Palm Beach Dental Assistant Champions Oral Health Through Local Outreach